Skip to main content
B

Beijing Konruns Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603590 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,198 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603590

About Beijing Konruns Pharmaceutical Co.,Ltd.

Beijing Konruns Pharmaceutical Co., Ltd. focuses on the research, development, and commercialization of innovative therapeutic solutions. The company specializes in surgical hemostasis and oncology. Its flagship product, Suling (Hemocoagulase Agkistrodon for Injection), is a proprietary hemostatic agent derived from snake venom, utilized in clinical surgical procedures to control bleeding. Konruns maintains an R&D pipeline centered on targeted cancer therapies, including KC1036, a multi-target kinase inhibitor for solid tumors. The organization integrates drug discovery, clinical development, and manufacturing processes to address unmet medical needs in hematology and metabolic diseases. Its strategic focus remains on high-value clinical innovation and the advancement of proprietary chemical and biological drug candidates.

Recent filings

Filing Released Lang Actions
康辰药业第五届董事会第二次会议决议公告
Regulatory Filings Classification · 1% confidence The document is an official disclosure announcing the resolutions of the company’s fifth board meeting (Board Meeting minutes) covering items such as approval of the 2025 annual report, profit distribution plan, remuneration proposals, audit firm appointments, funding usage reports, etc. It does not itself change board composition (so not MANG), nor is it a full report (10-K, IR), proxy materials, earnings release, or other specialized filings. It is a standard board resolution announcement under continuous disclosure obligations, fitting the fallback category for general regulatory announcements (RNS).
2026-04-22 Chinese
北京康辰药业股份有限公司对华兴会计师事务所（特殊普通合伙）履职情况评估的报告
Regulatory Filings Classification · 1% confidence The document is an in‐depth evaluation by a listed company of the performance of its external auditor during the 2025 audit engagement. It is not the auditor’s own audit report (no audit opinion on financial statements), nor is it an annual or interim financial report, earnings release, management discussion, or any other defined category. It doesn’t announce the publication of another report but instead provides substantive content on auditor evaluation. Therefore it falls into the general fallback category for miscellaneous regulatory filings.
2026-04-22 Chinese
康辰药业2025年年度利润分配方案公告
Notice of Dividend Amount Classification · 1% confidence The document is titled “2025年年度利润分配方案公告” and provides detailed information on per-share cash dividends, the base share count, total cash dividend amount, record date mechanics, board approval, and related risk disclosures. This is a classic dividend distribution plan announcement specifying dividend ratios and total payout. Therefore, it falls under “Notice of Dividend Amount” (DIV).
2026-04-22 Chinese
康辰药业2025年度募集资金存放、管理与使用情况鉴证报告
Audit Report / Information Classification · 1% confidence The document is a standalone CPA ‘鉴证报告’ (assurance report) on the company’s special report regarding the deposit, management, and use of raised funds (募集资金). It is not an announcement or summary but a full independent assurance report. This matches the ‘Audit Report / Information’ category (AR) which covers standalone audit and assurance reports, excluding full annual reports.
2026-04-22 Chinese
康辰药业董事会审计委员会对华兴会计师事务所（特殊普通合伙）履行监督职责情况的报告
Audit Report / Information Classification · 1% confidence The document is a standalone report by the company’s board audit committee summarizing its supervision and evaluation of the external auditor’s 2025 annual financial and internal control audit. It is not the full annual report, earnings release, or a brief announcement but a detailed audit supervision report. This matches the Audit Report / Information category (AR).
2026-04-22 Chinese
关于回购注销部分激励对象已获授但尚未解除限售的限制性股票及调整回购价格的公告
Transaction in Own Shares Classification · 1% confidence The document is an official announcement by Beijing Kangchen Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of its own restricted shares granted under its 2023 incentive plan, including details on the quantity, price adjustment, funding source, legal opinion, and share capital impact. This is a share buyback (transaction in own shares) rather than a report of financing or general regulatory filing. Under the provided taxonomy, this falls under “Transaction in Own Shares” (Code: POS).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.